期刊文献+

PON-1基因多态性与PCI术后主要心血管事件相关性研究 被引量:2

Correlation between PON1 gene polymorphism and major cardiovascular events after PCI
下载PDF
导出
摘要 目的:探讨影响经皮冠状动脉介入术(PCI)预后的危险因素,并分析冠状动脉介入术患者PON-1基因多态性与PCI术后主要心血管事件(MACE)的相关性。方法:选取冠状动脉介入术患者362例,采用聚合酶链式反应-限制性片段长度多态性技术(PCR-RFCP)检测各组PON1Q192R基因的多态性,统计分析患者住院期间与术后6个月随访期间患者MACE的发生情况,分析PON1基因Q192R多态性与PCI术后MACE发生的相关性。结果:PON1基因Q192R的多态性与MACE发生无明显相关。结论:PON1基因Q192R的多态性与冠心病患者PCI术后主要心血管事件发生的危险因素无关,但需要更多的研究证实。 Objective: To investigate the risk factors influencing the prognosis of patients with coronary artery intervention, and analyze the correlation between PON-1 gene polymorphism and the major adverse cardiovascular events after PCI.Methods: 362 patients with PCI were selected, PON1 Q192R polymorphism was detected with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technology.All the patients were followed up 6 months, the incidence of MACE during the period was monitored and recorded.The correlation between PON1 gene polymorphism and MACE was analyzed.Results:The incidence of MACE after PCI was not significantly correlated with PON1 gene polymorphism.Conclusion:There is no correlation between MACE and PON1 gene polymorphism, but more high quality investigation is in need.
出处 《陕西医学杂志》 CAS 2017年第4期417-418,425,共3页 Shaanxi Medical Journal
基金 陕西省教育厅基金资助项目(12JK0771)
关键词 经皮冠状动脉介入治疗 @PON-1 血小板聚集 @主要心血管事件 Percutaneous Coronary Intervention @PON1 @Major adverse cardiovascular events
  • 相关文献

参考文献8

二级参考文献125

  • 1赖凌云,顾勇,陈靖,郁胜强,马骥,杨海春,林善锬.大鼠系膜细胞醛固酮的合成及其对细胞外基质生成的影响[J].中华医学杂志,2003,83(21):1900-1905. 被引量:28
  • 2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2108
  • 3Gurbel PA,Bliden KP,Hayes KM,Yoho JA,Herzog WR,Tantry US.The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.J Am Coll Cardiol 2005; 45:1392-1396.
  • 4Desai NR,Mega JL,Jiang S,Cannon CP,Sabatine MS.Interaction between cigarette smoking and clinical benefit of clopidogrel.J Am Coll Cardio12009; 53:1273-1278.
  • 5de Morais SM,Wilkinson GR,Blaisdell J,Nakamura K,Meyer UA,Goldstein JA.The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.J Biol Chem 1994; 269:15419-15422.
  • 6Goldstein JA.Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.Br J Clin Pharmacol 2001; 52:349-355.
  • 7Bertilsson L.Geographical/interracial differences in polymorphic drug oxidation.Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.Clin Pharmacokinet 1995; 29:192-209.
  • 8Motovska Z,Widimsky P,Petr R,Bilkova D,Marinov I,Simek S,et al.Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention:statin's advantage and the smoking "paradox".J Cardiovasc Pharmacol 2009; 53:368-372.
  • 9Price MJ,Nayak KR,Barker CM,Kandzari DE,Teirstein PS.Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.Am J Cardiol 2009; 103:1339-1343.
  • 10Yang G,Fan L,Tan J,Qi G,Zhang Y,Samet JM,et al.Smoking in China:findings of the 1996 National Prevalence Survey.JAMA 1999; 282:1247-1253.

共引文献52

同被引文献23

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部